MAPT and early-onset autosomal dominant Alzheimer disease: This precludes the ability to confirm that these participants were not in the preclinical stage of Alzheimer’s disease (i.e. positive for Aβ and tau pathologies) or free from pathology found in other neurodegenerative diseases (e.g. a-synuclein and TDP-43).